---
title: "FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286594661.md"
description: "FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News"
datetime: "2026-05-15T08:45:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286594661.md)
  - [en](https://longbridge.com/en/news/286594661.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286594661.md)
---

# FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) | RHHBY Stock News](https://longbridge.com/en/news/286036724.md)
- [Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD  | RHHBY Stock News](https://longbridge.com/en/news/283530415.md)
- [BeOne's Venclexta challenger Beqalzi nets FDA approval](https://longbridge.com/en/news/286315985.md)
- [Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics | RHHBY Stock News](https://longbridge.com/en/news/285486114.md)
- [Switzerland's Roche agrees to acquire US-based PathAI](https://longbridge.com/en/news/285490796.md)